Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solitary Fibrous Tumors × repotrectinib × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Plasma cell 1 Lymphoid 1 CNS 1

Conditions

Solitary Fibrous Tumors 1 Sarcoma 1 Neoplasm Metastasis 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Lymphoma 1 Liver Diseases 1 Granuloma, Plasma Cell 1 Glioma 1 Glioblastoma 1

Interventions

repotrectinib 1 Suspensions 1 Capsules 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting

CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡